These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 8706769

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Haemodynamic dose-efficacy of levosimendan in healthy volunteers.
    Lilleberg J, Sundberg S, Häyhä M, Akkila J, Nieminen MS.
    Eur J Clin Pharmacol; 1994; 47(3):267-74. PubMed ID: 7867680
    [Abstract] [Full Text] [Related]

  • 3. The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
    Harjola VP, Oikarinen L, Toivonen L, Jurkko R, Puttonen J, Sarapohja T, Sundberg S, Nieminen MS.
    Int J Clin Pharmacol Ther; 2008 Aug; 46(8):389-99. PubMed ID: 18793580
    [Abstract] [Full Text] [Related]

  • 4. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA, Wagstaff AJ.
    Drugs; 2003 Aug; 63(23):2651-71. PubMed ID: 14636085
    [Abstract] [Full Text] [Related]

  • 5. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M, Lehtonen L.
    Curr Pharm Des; 2005 Aug; 11(4):435-55. PubMed ID: 15725064
    [Abstract] [Full Text] [Related]

  • 6. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects.
    Sundberg S, Lehtonen L.
    Eur J Clin Pharmacol; 2000 Aug; 55(11-12):793-9. PubMed ID: 10805056
    [Abstract] [Full Text] [Related]

  • 7. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y.
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [Abstract] [Full Text] [Related]

  • 8. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L.
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [Abstract] [Full Text] [Related]

  • 9. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan.
    Antila S, Honkanen T, Lehtonen L, Neuvonen PJ.
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):446-9. PubMed ID: 9726699
    [Abstract] [Full Text] [Related]

  • 10. Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
    Biala A, Martonen E, Kaheinen P, Levijoki J, Finckenberg P, Merasto S, Louhelainen M, Muller DN, Luft FC, Mervaala E.
    Hypertens Res; 2010 Oct; 33(10):1004-11. PubMed ID: 20811386
    [Abstract] [Full Text] [Related]

  • 11. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men.
    Sundberg S, Lilleberg J, Nieminen MS, Lehtonen L.
    Am J Cardiol; 1995 May 15; 75(15):1061-6. PubMed ID: 7747690
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
    Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ.
    J Clin Pharmacol; 2002 Jan 15; 42(1):43-51. PubMed ID: 11808823
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
    Udvary E, Papp JG, Végh A.
    Br J Pharmacol; 1995 Feb 15; 114(3):656-61. PubMed ID: 7735692
    [Abstract] [Full Text] [Related]

  • 14. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock.
    Oldner A, Konrad D, Weitzberg E, Rudehill A, Rossi P, Wanecek M.
    Crit Care Med; 2001 Nov 15; 29(11):2185-93. PubMed ID: 11700420
    [Abstract] [Full Text] [Related]

  • 15. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
    Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W.
    Circulation; 2000 Oct 31; 102(18):2222-7. PubMed ID: 11056096
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.
    Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L, Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study.
    Lancet; 2002 Jul 20; 360(9328):196-202. PubMed ID: 12133653
    [Abstract] [Full Text] [Related]

  • 18. Levosimendan, a new calcium-sensitizing inotrope for heart failure.
    Ng TM.
    Pharmacotherapy; 2004 Oct 20; 24(10):1366-84. PubMed ID: 15628834
    [Abstract] [Full Text] [Related]

  • 19. Levosimendan.
    Figgitt DP, Gillies PS, Goa KL.
    Drugs; 2001 Oct 20; 61(5):613-27; discussion 628-9. PubMed ID: 11368286
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.